×
Back to Agenda
Biosimilars and Generics: Access Versus Innovation
Session Chair(s)
Kurt R. Karst, JD
Director, Prescription Drugs and Biologics, Corporate Transactions, Enforcement, Hyman, Phelps & McNamara, PC, United States
This panel will review the balance between expediting generics to market for pricing balance based on competition and the need for the innovation of new drugs (e.g., EpiPen pricing and competitors).
Learning Objective : Recognize the need for continued innovation with the need to expedite approvals for generics and biosimilars.
Speaker(s)
Panelist
Executive Director , The Biosimilars Council, United States
Panelist
Executive Vice President for Clinical Affairs, America's Health Insurance Plans (AHIP), United States
Have an account?